26 results
8-K
VIR
Vir Biotechnology Inc
3 Oct 23
Entry into a Material Definitive Agreement
8:01am
will also receive approximately $11 million of additional funding under the BARDA Agreement to wind down activities for the PENINSULA trial … circulating COVID-19 variants and the potential benefits of alternative mAb delivery technologies in pandemic preparedness and response; wind down activities
8-K
EX-99.1
VIR
Vir Biotechnology Inc
2 Nov 23
Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2023 Financial Results
4:09pm
with BARDA supporting the wind down of the Company’s Phase 2 PENINSULA trial in the third quarter of 2023.
Cost of Revenue: Cost of revenue
8-K
EX-99.1
ib9dd
22 Feb 24
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
4:12pm
DRS
EX-10.54
acs3uae53 1tnoz3qg
23 Jun 20
Draft registration statement
12:00am
DRS
EX-10.56
jj6v58dbl9m51vt
23 Jun 20
Draft registration statement
12:00am
S-1
EX-10.16
05t1nii 5tg
3 Sep 19
IPO registration
4:40pm
DRS/A
EX-10.16
fxrxjtakt
7 Aug 19
Draft registration statement (amended)
12:00am
S-3ASR
lwqm 59p0
10 Nov 20
Automatic shelf registration
5:13pm
DRS
EX-3.1
a5mwo4j6 aoejttii
27 Jun 19
Draft registration statement
12:00am
DRS/A
EX-10.17
0at1b
7 Aug 19
Draft registration statement (amended)
12:00am
S-1
EX-10.17
17a0w 91lb2xg1
3 Sep 19
IPO registration
4:40pm
DRS
EX-10.58
bajeh
23 Jun 20
Draft registration statement
12:00am